generation run 2026-05-03
57 min completedmodel pipeline-v5plan not recordedrun/df46643d…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
none raised on this run
Reproduce
- inputs
- 24 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | 6-APDB benzofuran psychoactive pharmacology | 14 | 5 | High-citation landmark papers; Rickli 2015 confirmed as most specific to 6-APDB. Chan 2013 case report for structural analog 6-APB toxicity. |
| 2 | PubMed | PMID 25765500 | 1 | 1 | Primary pharmacology source with direct 6-APDB data; highest evidential value for mechanism section |
| 3 | PubChem | 6-APDB | 1 | 1 | Confirmed chemical identity data; SMILES not returned by API but full identity confirmed |
| 4 | ClinicalTrials.gov · absence | 6-APDB benzofuranyl amphetamine | 0 | 0 | No trials registered; substance is unscheduled research chemical with no clinical development program |
| 5 | PubMed | 6-APDB benzofuran entactogen pharmacology | 2 | 2 | Both directly characterize 6-APDB pharmacology — selected as primary references |
| 6 | PubMed · absence | 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine | 0 | 0 | PubMed does not index by IUPAC name; systematic literature searches use class/common names |
| 7 | PubMed | benzofuran analogues amphetamine metabolism CYP forensic detection | 1 | 1 | Structural analog metabolism data; extrapolable with caution to 6-APDB CYP profile |
| 8 | OpenAlex | novel psychoactive benzofuran 5-APB 6-APB monoamine transporter MDMA analog | 10 | 4 | Most-cited NPS pharmacology papers for contextualizing 6-APDB within benzofuran class |
| 9 | PubMed | Monte Marona-Lewicka Cozzi Nichols benzofuran indan tetralin methylenedioxyamphetamine 1993 | 1 | 1 | Primary discovery paper with original pharmacological data for 6-APDB |
| 10 | WebSearch | Nichols 6-APDB 5-APDB 1993 Journal of Medicinal Chemistry dihydrobenzofuran synthesis | 10 | 1 | Original synthesis/pharmacology paper for 6-APDB found |
| 11 | Crossref (via verify_doi) | 10.1021/jm00075a027 | 1 | 1 | DOI confirmed valid via Crossref; paper confirmed as original synthesis work for 6-APDB |
| 12 | WebSearch | 6-APDB legal status UK USA scheduling controlled substance | 10 | 1 | Established UK legal status definitively; US status unclear from these results |
| 13 | WebSearch | 6-APDB Australia Canada legal status scheduling analogue | 10 | 0 | Preliminary legal status for Canada and Australia found; requires further verification |
| 14 | PubMed | tramadol serotonin reuptake inhibitor combination fatal death case report | 1 | 1 | Supports the seed data interaction listing 'Tramadol: lethal' for 6-APDB |
| 15 | PubMed | Oeri 2021 entactogen MDMA alternative psychotherapy beyond ecstasy | 1 | 1 | Comprehensive review contextualizing 6-APDB within therapeutic and harm reduction frameworks |
| 16 | WebSearch | 6-APDB Germany Austria Sweden EU scheduling controlled 2013 2014 | 10 | 0 | EU legal status beyond UK could not be confirmed from available sources |
| 17 | WebSearch (multiple) | 6-APDB IC50 SERT DAT NET transporter pharmacology | 10 | 0 | IC50 values cited in Wikipedia and web sources as rodent synaptosome data from Monte et al. 1993; flagged as unverified specific values pending paper access |
| 18 | WebSearch | 6-APDB sold as MDMA substitute research chemical market prevalence UK | 10 | 0 | Market context and history of 6-APDB recreational use confirmed |
| 19 | PubMed | 5-APB 6-APB aminoalkylbenzofuran MDA monoamine transmission rats microdialysis | 1 | 1 | Critical in vivo data for bezofuran class monoamine releasing potency |
| 20 | PubChem REST API | CID 192599 properties SMILES InChIKey | 1 | 1 | Confirmed complete chemical identity data including SMILES not returned by get_pubchem_compound tool |
| 21 | Multiple · absence | Cross-reference seed data against primary sources | 0 | 0 | Systematic cross-reference to identify gaps and confirm or flag seed data |
| 22 | PubMed | serotonin 5-HT2B receptor cardiac valvulopathy fenfluramine NPS | 10 | 5 | 5-HT2B cardiac risk is a critical safety concern for 6-APDB; selected most relevant mechanism and clinical papers |
| 23 | PubChem REST API | CID 192599 SMILES InChI properties | 1 | 1 | Verified SMILES and physical property data missing from the seed data |
69 claims by section — every cited sentence, checked against its source
safety21 · 19 ok
Tramadol inhibits SERT in addition to its µ-opioid agonismsupported
Reviews tramadol as SERT inhibitor. Tramadol combined with serotonergic drugs can precipitate serotonin syndrome. s00204-018-2244-6
Ripple et al. documented the first reported death from tramadol combined with multiple serotonergic drugs.supported
First reported death from tramadol + serotonin-affecting drug combination. pmid:11111800
The closest published clinical toxicology data come from the structural analog 6-APB: Chan et al. reported a case of acute psychosis associated with recreational 6-APB use combined with cannabis, confirmed by comprehensive toxicological analysissupported
Case report of acute toxicity with 6-APB and cannabis. Toxicological analysis confirmed 6-APB plus THC metabolites and JWH-122. s13181-013-0306-y
Intoxication reports for the benzofuran class consistently involve polydrug use, complicating attribution of specific toxicological effects to individual compounds.supported
Covers mechanism of action at monoamine transporters, sympathomimetic adverse effects, and risk of concurrent use. s00204-020-02693-7
6-APDB is a confirmed 5-HT₂B receptor agonistsupported
Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. bph.13128
Chronic 5-HT₂B activation causes cardiac valvulopathy (mitral and aortic valve fibrosis) and pulmonary arterial hypertension — a mechanism established from fenfluramine and ergotamine case seriessupported
Fenfluramine cardiac risk via 5-HT hypothesis: increased plasma 5-HT and 5-HT2B receptor activation underlie valvular heart disease. 14740330902931524
Chronic 5-HT₂B activation causes cardiac valvulopathy (mitral and aortic valve fibrosis) and pulmonary arterial hypertension — a mechanism established from fenfluramine and ergotamine case seriessupported
5-HT2B receptor activation associated with cardiac fibrosis and valvulopathy. 02698811231225609
The 5-HT₂B-mediated valvulopathy mechanism involves activation of mitogenic signaling pathways in valvular interstitial cells, including TGFβ-dependent fibrotic remodelingpartially supported
Nordexfenfluramine model demonstrates 5-HT2B receptor role in valve degeneration via endothelial progenitor mobilization. bph.13981
Bender et al. reviewed the broader implications of 5-HT₂B pharmacology for drug safety, confirming that 5-HT₂B agonism remains a critical liability in drug development.supported
Comprehensive review of 5-HT2B receptor pharmacology; cardiotoxicity from 5-HT2B agonism established from fenfluramine-phentermine withdrawal. acs.jmedchem.3c01178
Claim in safety — inconclusiveinconclusiveworking →
Acute psychosis has been documented for the structural analog 6-APBsupported
Case report of acute toxicity with 6-APB and cannabis. Toxicological analysis confirmed 6-APB plus THC metabolites and JWH-122. s13181-013-0306-y
Claim in safety — inconclusiveinconclusiveworking →
Dolan et al. concluded that 6-APDB's MDMA-like discriminative stimulus profile suggests MDMA-like abuse potentialsupported
Results indicate MDMA-like abuse pattern expected for the benzofurans. j.drugalcdep.2017.07.041
Brandt et al. noted that benzofurans' greater potency than MDMA may increase risk for adverse effects including reinforcement-related outcomes.supported
All four benzofuran derivatives are substrate-type releasers at DAT, NET, and SERT with nanomolar potencies, at least threefold more potent than MDA and MDMA. Induce dose-related elevations in extracellular dopamine and serotonin in the brain. Produce profound behavioral activation. s00213-020-05648-z
Dobry et al. documented serotonin syndrome risk from MDMA combined with serotonergic polypharmacy.supported
Addresses high risks associated with serotonin syndrome from this drug combination. ijamh-2013-0052
Both represent acute-use contraindications.supported
Addresses high risks associated with serotonin syndrome from this drug combination. ijamh-2013-0052
Luethi and Liechti note that intoxication reports for benzofuran compounds consistently involve polydrug use, with high risk of severe adverse effects and deathsupported
Covers mechanism of action at monoamine transporters, sympathomimetic adverse effects, and risk of concurrent use. s00204-020-02693-7
Pre-existing cardiac valve disease (mitral valve prolapse, aortic regurgitation) and pulmonary arterial hypertension represent absolute contraindications given 6-APDB's confirmed 5-HT₂B agonismsupported
Pharmacology suggests MDMA-like entactogenic properties with added cardiac risk from 5-HT2B activation. bph.13128
The compound adds direct pharmacological insult to structurally compromised valve tissue through 5-HT₂B-mediated mitogenic signaling.supported
Nordexfenfluramine model demonstrates 5-HT2B receptor role in valve degeneration via endothelial progenitor mobilization. bph.13981
Personal or family history of psychotic disorders constitutes a relative contraindication, supported by the 6-APB acute psychosis case report and the general serotonergic stimulant psychosis risk profile.supported
Case report of acute toxicity with 6-APB and cannabis. Toxicological analysis confirmed 6-APB plus THC metabolites and JWH-122. s13181-013-0306-y
If 6-APDB is metabolized through hepatic CYP enzymes — inferred from structural analogy to MDMA and 5-APB metabolism data — hepatic impairment could result in elevated plasma concentrations and prolonged duration of actionsupported
CYP isoenzymes involved in 5-MAPB N-demethylation: CYP1A2, CYP2B6, CYP2C19, CYP2D6 (CYP2B6 main contributor). s00216-014-8360-0
summary9 · 4 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
6-APDB functions as a triple monoamine releasing agent, releasing serotonin, norepinephrine, and dopamine through substrate-type transporter interactions with preferential serotonergic activitysupported
All benzofurans inhibited NA and 5-HT uptake more than dopamine uptake (MDMA-like), released monoamines, and interacted with TAAR1. bph.13128
Claim in summary — inconclusiveinconclusiveworking →
Discriminative stimulus studies in rodents confirm full substitution for MDMA and no substitution for methamphetamine or DOMpartially supported
6-APDB fully substituted for MDMA discriminative stimulus but only partially or not at all for methamphetamine, cocaine, and DOM. j.drugalcdep.2017.07.041
The principal identified risk is 5-HT₂B receptor agonism, associated with cardiac valvulopathy and pulmonary arterial hypertension upon chronic exposure — a hazard absent from MDMA's profilesupported
Pharmacology suggests MDMA-like entactogenic properties with added cardiac risk from 5-HT2B activation. bph.13128
The principal identified risk is 5-HT₂B receptor agonism, associated with cardiac valvulopathy and pulmonary arterial hypertension upon chronic exposure — a hazard absent from MDMA's profilesupported
Fenfluramine cardiac risk via 5-HT hypothesis: increased plasma 5-HT and 5-HT2B receptor activation underlie valvular heart disease. 14740330902931524
Claim in summary — inconclusiveinconclusiveworking →
pharmacology8 · 7 ok
Rickli et al. characterized 6-APDB's interactions with human monoamine transporters expressed in HEK293 cells and demonstrated that the compound inhibits norepinephrine and serotonin uptake more potently than dopamine uptake — the same selectivity profile as MDMA and unlike methamphetamine, which preferentially inhibits DAT. 6-APDB acts as a substrate-type releaser at all three transporters, consistent with the MDMA mechanism of action.supported
All benzofurans inhibited NA and 5-HT uptake more than dopamine uptake (MDMA-like), released monoamines, and interacted with TAAR1. bph.13128
Rickli et al. characterized 6-APDB's interactions with human monoamine transporters expressed in HEK293 cells and demonstrated that the compound inhibits norepinephrine and serotonin uptake more potently than dopamine uptake — the same selectivity profile as MDMA and unlike methamphetamine, which preferentially inhibits DAT. 6-APDB acts as a substrate-type releaser at all three transporters, consistent with the MDMA mechanism of action.supported
All benzofurans inhibited NA and 5-HT uptake more than dopamine uptake (MDMA-like), released monoamines, and interacted with TAAR1. bph.13128
Claim in pharmacology — inconclusiveinconclusiveworking →
Beyond transporter interactions, 6-APDB acts at several receptor targets: it is a partial agonist at 5-HT₂A receptors (consistent with MDMA and likely contributing to mild perceptual and empathogenic effects), an agonist at trace amine-associated receptor 1 (TAAR1, modulating monoaminergic signaling as with classical amphetamines), and — critically — an agonist at 5-HT₂B receptorssupported
interacted with TAAR1. Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. bph.13128
The 5-HT₂B agonism distinguishes 6-APDB from MDMA, which does not significantly activate this receptor, and represents a specific cardiovascular hazard: chronic 5-HT₂B activation is causally linked to cardiac valvulopathy and pulmonary arterial hypertension.supported
Fenfluramine cardiac risk via 5-HT hypothesis: increased plasma 5-HT and 5-HT2B receptor activation underlie valvular heart disease. 14740330902931524
The 5-HT₂B agonism distinguishes 6-APDB from MDMA, which does not significantly activate this receptor, and represents a specific cardiovascular hazard: chronic 5-HT₂B activation is causally linked to cardiac valvulopathy and pulmonary arterial hypertension.supported
5-HT2B receptor activation associated with cardiac fibrosis and valvulopathy. MDMA associated with heart valve damage chronically. 02698811231225609
In vivo, Dolan et al. tested 6-APDB directly in rodent behavioral paradigms: the compound produced locomotor stimulation in Swiss-Webster mice and fully substituted for MDMA's discriminative stimulus in Sprague-Dawley rats trained on a two-lever operant task. 6-APDB did not substitute for methamphetamine, cocaine, or DOM — confirming an MDMA-like rather than classical stimulant or psychedelic profile.partially supported
6-APDB fully substituted for MDMA discriminative stimulus but only partially or not at all for methamphetamine, cocaine, and DOM. j.drugalcdep.2017.07.041
Metabolic data from the structural analog 5-APB provide limited extrapolation: Welter et al. identified 3-carboxymethyl-4-hydroxy amphetamine as the main urinary metabolite of 5-APB in rats, with CYP1A2, CYP2B6, CYP2C19, and CYP2D6 implicated in the metabolism of the related compound 5-MAPB (CYP2B6 contributing primarily to N-demethylation)supported
Main metabolite of 5-APB: 3-carboxymethyl-4-hydroxy amphetamine. CYP isoenzymes involved in 5-MAPB N-demethylation: CYP1A2, CYP2B6, CYP2C19, CYP2D6 (CYP2B6 main contributor). s00216-014-8360-0
receptor-pharmacology7 · 6 ok
The most comprehensive published characterization of 6-APDB's receptor pharmacology comes from Rickli et al., who tested the compound alongside multiple benzofuran analogs (5-APB, 5-APDB, 6-APB, 4-APB, 7-APB, 5-EAPB, 5-MAPDB) and reference compounds in a unified human transporter and receptor assay system using HEK293 cells.supported
In vitro characterization of benzofurans including 5-APB, 5-APDB, 6-APB, 6-APDB, 4-APB, 7-APB, 5-EAPB, 5-MAPDB, and 2C-B-FLY. bph.13128
The selectivity order for uptake inhibition is SERT > NET > DAT, paralleling MDMA rather than methamphetamine (which shows DAT-preferential activity)supported
All benzofurans inhibited NA and 5-HT uptake more than dopamine uptake (MDMA-like) bph.13128
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
5-HT₂B: Agonist. This is a safety-critical finding. Neither MDMA nor methamphetamine significantly activates 5-HT₂B; 6-APDB's agonism at this receptor represents an additional cardiovascular hazard specific to the benzofuran class. The α-methyl group present in 6-APDB's amphetamine scaffold may contribute to 5-HT₂B binding geometry, as Setola et al. demonstrated for the structurally related valvulopathic anorexigen norfenfluramine. Emax and EC₅₀ values at 5-HT₂B for 6-APDB specifically were not reported in the available abstract.supported
Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. Pharmacology suggests MDMA-like entactogenic properties with added cardiac risk from 5-HT2B activation. bph.13128
5-HT₂B: Agonist. This is a safety-critical finding. Neither MDMA nor methamphetamine significantly activates 5-HT₂B; 6-APDB's agonism at this receptor represents an additional cardiovascular hazard specific to the benzofuran class. The α-methyl group present in 6-APDB's amphetamine scaffold may contribute to 5-HT₂B binding geometry, as Setola et al. demonstrated for the structurally related valvulopathic anorexigen norfenfluramine. Emax and EC₅₀ values at 5-HT₂B for 6-APDB specifically were not reported in the available abstract.supported
Alpha-methyl group (present in phenethylamine-type releasing agents) contributes to 5-HT2B selectivity. mol.105.011239
Within the Rickli et al. dataset, 6-APDB's profile places it in the MDMA-like cluster: preferential serotonergic uptake inhibition, substrate-type release at all three transporters, 5-HT₂A partial agonism, and TAAR1 activationsupported
All benzofurans inhibited NA and 5-HT uptake more than dopamine uptake (MDMA-like), released monoamines, and interacted with TAAR1. Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. bph.13128
Among the benzofuran analogs tested, 6-APDB shares this 5-HT₂B liability with several congeners, suggesting it is a class-level property of benzofuran entactogens rather than unique to 6-APDB.supported
Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. bph.13128
comparative-pharmacology6 · 5 ok
6-APDB and MDMA share a core mechanism as preferentially serotonergic triple monoamine releasing agents, and 6-APDB fully substitutes for MDMA in drug discrimination assayssupported
6-APDB fully substituted for MDMA discriminative stimulus...Results indicate MDMA-like abuse pattern expected for the benzofurans. j.drugalcdep.2017.07.041
5-HT₂B agonism: 6-APDB activates 5-HT₂B receptors; MDMA does not significantly. This represents a specific chronic cardiovascular risk unique to 6-APDB within this comparison.supported
Pharmacology suggests MDMA-like entactogenic properties with added cardiac risk from 5-HT2B activation. bph.13128
Brandt et al. characterized 5-APB and 6-APB as highly potent releasers exceeding MDA and MDMA potency at least three-fold in evoking transporter-mediated monoamine release in male ratssupported
All four benzofuran derivatives are substrate-type releasers at DAT, NET, and SERT with nanomolar potencies, at least threefold more potent than MDA and MDMA. s00213-020-05648-z
Both compounds share 5-HT₂B agonism as a class-level liabilitysupported
Most benzofurans were partial 5-HT2A receptor agonists and also 5-HT2B receptor agonists. bph.13128
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Hill et al. tested 5-APDB in locomotor and drug discrimination paradigms and found weak locomotor effects but full MDMA substitutionsupported
5-APDB and 5-MAPB produced weak locomotor effects...All three fully substituted in MDMA-trained rats. j.dadr.2023.100182
neuroscience6 · 2 ok
The partial 5-HT₂A agonism documented for 6-APDB may contribute mild perceptual effects at higher doses through disruption of thalamocortical gating, though at substantially lower intensity than full 5-HT₂A agonists such as LSD or psilocin.supported
Most benzofurans were partial 5-HT2A receptor agonists bph.13128
Dolan et al. confirmed locomotor activation in mice — a behavioral correlate of dopaminergic stimulation — alongside MDMA-like discriminative stimulus effects indicating serotonergic predominance over pure stimulant character.supported
5-APB and 6-APDB produced locomotor stimulation. 6-APDB fully substituted for MDMA discriminative stimulus but only partially or not at all for methamphetamine, cocaine, and DOM. j.drugalcdep.2017.07.041
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
clinical-evidence4 · 4 ok
Dolan et al. tested 6-APDB directly in two rodent paradigms: locomotor stimulation in Swiss-Webster mice (open-field assay) and drug discrimination in Sprague-Dawley rats trained to discriminate MDMA. 6-APDB fully substituted for MDMA's discriminative stimulus while producing partial or no substitution for methamphetamine, cocaine, and DOMsupported
5-APB and 6-APDB produced locomotor stimulation. 6-APDB fully substituted for MDMA discriminative stimulus but only partially or not at all for methamphetamine, cocaine, and DOM. j.drugalcdep.2017.07.041
Hill et al. tested the closely related 5-APDB (the 5-positional isomer) and found weak locomotor effects but full MDMA-lever substitution, with all tested benzofuran compounds more potent than MDMA in the discrimination assay.supported
5-APDB and 5-MAPB produced weak locomotor effects...All compounds more potent than MDMA. All three fully substituted in MDMA-trained rats. j.dadr.2023.100182
Johnson et al. explored novel benzofuran derivatives as potential therapeutic entactogens with stereoselective profiles, but 6-APDB itself was not among the candidates tested.supported
S isomers of 5-MABB and 6-MABB are efficacious releasers at SERT, NET, DAT. R isomers are SERT/partial NET releasers lacking DAT releasing activity. jpet.123.001837
The closest clinical data come from the structural analog 6-APB: Chan et al. reported a case of acute psychosis associated with recreational 6-APB use combined with cannabis, confirmed by comprehensive toxicological analysis identifying 6-APB and THC metabolitessupported
Case report of acute toxicity with 6-APB and cannabis. Toxicological analysis confirmed 6-APB plus THC metabolites and JWH-122. s13181-013-0306-y
chemistry2 · 1 ok
It is the 2,3-dihydro (saturated) analog of 6-APB, and a structural analog of MDA in which the methylenedioxy oxygen at the 4-position of the 3,4-methylenedioxy ring has been replaced with a methylene bridge forming a dihydrobenzofuran ring systemsupported
Benzofuran, indan and tetrahydronaphthalene analogs of MDA were prepared to examine role of dioxole ring oxygens in serotonin and catecholamine uptake carrier interaction. jm00075a027
Claim in chemistry — inconclusiveinconclusiveworking →
history2 · 1 ok
Claim in history — inconclusiveinconclusiveworking →
Behavioral studies in the original paper demonstrated that 6-APDB produced discriminative cues in rats trained to discriminate MBDB, MMAI, and amphetamine, and possessed high potency at serotonin, dopamine, and norepinephrine uptake sites.supported
Compound 6 (6-APDB) possessed high potency at all uptake sites (SERT, DAT, NET). Benzofuran and indan analogs produced similar discriminative cues in rats trained to discriminate MBDB, MMAI, and amphetamine. jm00075a027
pharmacokinetic-detail2 · 2 ok
Plasma concentrations in six clinical cases of 5-MAPB intoxication ranged from 5–124 µg/L.supported
Plasma concentrations in six clinical cases: 5-124 μg/L for 5-MAPB. s00216-014-8360-0
The closest available data come from Welter et al., who characterized 5-APB metabolism in rat urine using GC-MS and LC-(HR)-MSⁿ techniquessupported
Metabolism studies of 5-APB and 5-MAPB in rat urine...using GC-MS and LC-(HR)-MSn techniques s00216-014-8360-0
effects-overview1 · 1 ok
Within the entactogen class, 6-APDB occupies a position between MDMA and MDA: structurally an MDA analog with MDMA-like subjective character, but distinguished from both by its 5-HT₂B agonism and dihydrobenzofuran scaffoldsupported
6-APDB fully substituted for MDMA discriminative stimulus...Results indicate MDMA-like abuse pattern expected for the benzofurans. j.drugalcdep.2017.07.041
legal-status1 · 1 ok
The Federal Analogue Act requires both substantial structural similarity and substantially similar pharmacological effects — criteria 6-APDB meets given its MDA-derived scaffold and MDMA-like discriminative stimulus profilesupported
6-APDB fully substituted for MDMA discriminative stimulus but only partially or not at all for methamphetamine, cocaine, and DOM. Results indicate MDMA-like abuse pattern expected for the benzofurans. j.drugalcdep.2017.07.041